Evidence suggests that some nonsteroidal anti-inflammatory drugs (NSAIDs) possess antibacterial properties with an unknown mechanism. We describe the in vitro antibacterial properties of the NSAIDs carprofen, bromfenac, and vedaprofen, and show that these NSAIDs inhibit the Escherichia coli DNA polymerase III β subunit, an essential interaction hub that acts as a mobile tether on DNA for many essential partner proteins in DNA replication and repair. Crystal structures show that the three NSAIDs bind to the sliding clamp at a common binding site required for partner binding. Inhibition of interaction of the clamp loader and/or the replicative polymerase α subunit with the sliding clamp is demonstrated using an in vitro DNA replication assay. NSAIDs thus present promising lead scaffolds for novel antibacterial agents targeting the sliding clamp.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of pain, fever and inflammation (Vonkeman and van de Laar, 2010) . Their mode of action is predominantly through inhibition of cyclooxygenases (COXs) to reduce synthesis of the pro-inflammatory mediator prostaglandin H 2 (Dinarello, 2010) . Other known targets of NSAIDs in inflammation include fatty acid amide hydrolase and phospholipase A2 (Singh et al., 2004; Bertolacci et al., 2013) . Several off-targets unrelated to inflammation have been identified, including aldo-ketoreductase 1C3 and retinoid X receptor-α. Binding to these proteins may explain some of the anti-proliferative effects of NSAIDs (Zhou et al., 2010; Flanagan et al., 2012) . Limited data suggest that NSAIDs possess antibacterial properties, although these are confounded by routine use of NSAIDs in combination with antibiotics (Origlieri and Bielory, 2009) , particularly in veterinary medicine (Elitok and Elitok, 2004; Lopez et al., 2007; Kromker et al., 2011) . Weak in vitro antibacterial activity has been demonstrated by ibuprofen and indomethacin (Shirin et al., 2006; Al-Janabi, 2010) , but there has been no report of a mechanism for this action.
Our studies on the Escherichia coli DNA polymerase III (Pol III) β subunit led to the discovery that the NSAID carprofen binds to and inhibits essential interactions of this protein. Pol III β, also known as the sliding clamp (SC) is a torus-shaped homodimer that is structurally conserved among all bacterial species (Burnouf et al., 2004; Argiriadi et al., 2006; Gui et al., 2011) and serves as a protein-protein interaction hub during DNA replication and repair (Dalrymple et al., 2001; Johnson and O'Donnell, 2005; Indiani and O'Donnell, 2006) .
After being loaded onto double-stranded DNA through interactions with the δ subunit of the Pol III clamp loader complex (composed of Pol III δ(γ/τ) 3 δ') (Naktinis et al., 1995; Jeruzalmi et al., 2001; Leu and O'Donnell, 2001) , the SC recruits a diverse range of protein binding partners, including the α and ε subunits of Pol III, DNA polymerases I, II, IV, and V, and MutS (Kong et al., 1992; Indiani and O'Donnell, 2006; Jergic et al., 2013) . This array of binding partners makes the SC one of the most trafficked elements in the cell (Bunting et al., 2003; Lopez de Saro, 2009; Robinson et al., 2012) . It confers high processivity upon the Pol III αεθ core (the replicase) by acting as a mobile tether (Beck et al., 2006; Kelch et al., 2011) .
A single binding pocket containing two subsites (I and II) (Burnouf et al., 2004; Georgescu et al., 2008) located on each of the SC monomers interacts with short linear clamp-binding motifs (CBMs) located in flexible C-terminal regions or internal loops of known protein binding partners (Kong et al., 1992; Shamoo and Steitz, 1999; Dalrymple et al., 2001) . Studies have identified a consensus CBM sequence QLx 1 Lx 2 F/L (where x is any amino acid; S or D preferred at x 1 ; x 2 may be absent) that interacts with the SC CBM-binding pocket, and isolated peptides based on this sequence bind the SC with affinities similar to their parent proteins (Wijffels et al., 2004; . Conversely, when CBMs are removed from parent proteins, they are observed to lose affinity for the SC (Dalrymple et al., 2001; Kongsuwan et al., 2006) .
Targeting the bacterial DNA replication machinery is a validated strategy for producing clinically useful antibiotics, as evidenced by the highly successful quinolones, DNA gyrase inhibitors (Kohanski et al., 2010) .
The bacterial SC is an emerging DNA replication target that is yet to be clinically validated (Robinson et al., 2012) . Modified peptides based on the consensus sequence show increased affinity to the clamp (Wolff et al., 2011; Wijffels et al., 2011) . Small molecules have been identified that bind to the CBM-binding pocket of the SC and inhibit interactions with polymerases, but no antibacterial activities have yet been reported (Georgescu et al., 2008; Wijffels et al., 2011) . These are RU7, a thioxothiazolinine derivative (Georgescu et al., 2008) , and a biphenyloxime ether derivative (Wijffels et al., 2011) . Both classes of compound bind in subsite I of the CBM-binding cleft. Our observation of the ability of the NSAID carprofen, described below, to bind to the identical site on the SC spurred us to initiate a broader exploration of the effects of NSAIDs on the SC.
Minimal inhibitory concentrations (MICs) were measured for a variety of NSAIDs to establish a correlation between SC binding and inhibition and in vitro antibacterial potencies. Biochemical assays using a minimal set of components for SC-dependent DNA replication were used to demonstrate inhibitory effects of NSAIDs on this essential process, and X-ray crystallography provided structural insights into NSAID-SC binding.
RESULTS

SC Inhibition and Antibacterial Potency
A fluorescence polarization (FP) competition assay (Yin et al., 2013) was used to assess the E. coli SC binding affinity of commercially available NSAIDs. A fluorescently labeled tracer peptide (5-carboxyfluorescein-QLDLF) based on the N-acetylated consensus pentapeptide AcQLDLF (Wijffels et al., 2011; Wolff et al., 2011) was used as the competitor ligand. Inhibition of tracer binding to the SC at various NSAID concentrations gave IC 50 values that were transformed into inhibition constants (K i ) using the Kenakin correction for ligand depletion (Kenakin, 1993 ). Twenty NSAIDs were tested (Table S1) Figure S1 ). Vedaprofen, bromfenac and carprofen showed the strongest effects (K i < 300 µM), while flufenamic and tolfenamic acids were weaker binders (K i values > 700 µM).
NSAIDs were tested for antibacterial activity using standard MIC assays with four species: Escherichia coli, Acinetobacter baylyi, Staphylococcus aureus and Bacillus subtilis. MICs evaluated as inhibited visible growth with varying concentrations of NSAIDs are provided in Table S1 . The Gram-positive species (S. aureus and B. subtilis) showed higher susceptibility to NSAIDs than the Gram-negative species (E. coli and A. baylyi), a trend also observed with four positive control antibiotics (Table S2 ). The additional permeability barrier of the outer membrane in Gram-negative species is likely responsible for these trends (Rigel and Silhavy, 2012) .
The antibacterial testing was repeated for the top-five SC inhibitors, vedaprofen, bromfenac, carprofen, and flufenamic and tolfenamic acids. The MICs were determined as lowest NSAID concentration with backgroundcorrected optical density of less than 0.1 after 24-hour bacterial growth (Table S3 ). The resulting MICs (Table   1 , data derived from Table S3 ) are consistent with results from visual inspections. These five NSAIDs that most potently inhibited E. coli SC binding in the FP assay were the same compounds that showed the highest level of antibacterial activity against Gram-positive species and were the only NSAIDs to show any activity against the Gram-negatives. NSAIDs that did not inhibit the E. coli SC all showed very low or negligible antibacterial activity (Table S1 ), consistent with inhibition of the SC giving rise to the antibacterial effects of NSAIDs. The consensus pentapeptide AcQLDLF (Wolff et al., 2011) showed high affinity for the E. coli SC (K i ~ 1 µM), but no antibacterial activity (Table S1 ), likely due to its inability to penetrate bacterial membranes (Bechara and Sagan, 2013) and/or susceptibility to aminopeptidase activity (Gonzales and Robert-Baudouy, 1996) .
NSAIDs Inhibit the E. coli SC through Binding to Subsite I of the CBM-Binding Pocket
The locations of binding of NSAIDs to the E. coli SC were demonstrated by X-ray crystallography. NSAID/E. coli SC co-crystal structures were obtained with each of the best SC binders, vedaprofen, bromfenac and carprofen. These complexes are denoted as SC Vedaprofen , SC Bromfenac and SC Carprofen . All three NSAIDs were found to bind in subsite I of the CBM-binding pocket ( Figure 1 ). Interestingly, while crystals were soaked in the presence of racemic mixtures of vedaprofen and carprofen, the 2mFo-DFc electron density maps suggested that (R)-vedaprofen and (S)-carprofen were the favored stereoisomers in the complexes ( Figure 1A , C).
Superimpositions of the NSAID-bound structures and their corresponding native crystal structures (obtained in the same crystal form) are shown in Figure 1A -C. Stereo diagrams of these complex structures are in Figure   S2 .
The cyclohexyl moiety of (R)-vedaprofen occupies a deep hydrophobic pocket in subsite I comprising the side chains of V247, L177, V360 and M362 ( Figure 1A ). The naphthalene rings occupy an adjacent, shallower region near P242. Binding of (R)-vedaprofen moved the side chains of R246 and R240 (relative to the apo-SC structure) towards the(R)-vedaprofen carboxylate, resulting in formation of a salt bridge between the carboxylate and the guanidinium moiety of R240. The side-chain of V247 adopted a flipped conformation relative to the apo structure, apparently as a result of steric interactions with the bulky cyclohexane group.
Additionally, the cyclohexyl ring caused rotation of the χ 2 angle of M362, a residue that acts as a "gate"
between subsites I and II, from -130° to -69°. The side-chain of S346 was also rotated in response to movements in M362.
The aryl bromide of bromfenac occupies the deep hydrophobic pocket of subsite I, with the aniline group residing in the adjacent shallower region ( Figure 1B ). The carboxylate of bromfenac makes no direct interactions with the binding site. Binding of bromfenac caused only minor structural perturbations in subsite I
with the exception of a rotated side chain at S346. The "gating" residue M362 retained the "closed" conformation (χ 2 of -171°), as observed in the apo-SC structure.
In the case of (S)-carprofen, the carbazole ring occupies the shallower region and the aryl chloride is buried in the adjacent deep pocket ( Figure 1C ). The carboxylate group of (S)-carprofen forms an H-bond with the sidechain phenol of Y154. The carbazole nitrogen is oriented outwards from the binding site and this pose appears to open the M362 gate, rotating its χ 2 angle from -174° to -58°. The only other change observed in subsite I is the rotation of the side-chain of S346.
The E. coli SC CBM-Binding Pocket is Conserved across Bacterial Species
Sequence alignments of the SCs (Figure 2A ) from the four bacterial species used in the antibacterial assays show that the 15 residues comprising subsites I (yellow) and II (cyan) of their respective CBM-binding pockets are very well conserved, especially in subsite I. Sequence alignments of the SCs from a total of nine bacterial species (five Gram-negatives and four Gram-positives) similarly showed highly conserved CBM-binding pocket sequences ( Figure S3 ).
The structures of SC Carprofen and the E. coli SC in complex with the Pol III δ subunit (PDB entry 1JQJ; Jeruzalmi et al., 2001 ) are overlaid in Figure 2B . Similarly, the structures of SC Carprofen and the SC in complex with the C-terminal CBM-peptide of the Pol III α subunit (PDB entry 3D1F; Georgescu et al., 2008) are overlaid in Figure 2C . The structures show that binding of the CBMs of both Pol III δ and α subunits span subsites I and II, with the LxF sub-motif of each peptide filling the pocket at subsite I occupied by the NSAIDs ( Figure 1A , B). High sequence conservation within the CBM-binding pockets of the various SC homologs suggests that these NSAIDs most likely bind to subsite I and inhibit the SCs of many bacterial species.
NSAIDs Inhibit in vitro DNA Replication
A SC-dependent DNA replication assay using a minimal set of components required for in vitro DNA replication was developed to explore inhibition of the E. coli SC by NSAIDs. In this assay, binding of CBMs from the δ and α subunits to the SC are essential for replication, meaning impaired SC binding due to the presence of NSAIDs will inhibit DNA synthesis. A synthetically RNA-primed circular single-stranded (ss) DNA coated with single-stranded DNA-binding protein (SSB) was used as template. The reaction system contained the SC, the Pol III α subunit and a reconstituted clamp loader complex (γ 3 δδ') to load the SC at the primer terminus ( Figure 3A ). The α subunit bound to the SC catalyses extension of the primer through incorporation of dNTPs using the ssDNA as template. Formation of double-strand DNA was tracked by agarose gel electrophoresis and is dependent on the SC concentration ( Figures S4A,B) .
As a positive control, the pentapeptide AcQLDLF (K i ~ 1 µM) (used as a model inhibitor) showed dosedependent inhibition of replication over the range of 1-10 µM (Figure 3b ), when added to the complete replication system. A titration was also carried out by pre-incubating the reaction system before the addition of the α subunit and the AcQLDLF pentapeptide, hoping to distinguish the inhibition of DNA synthesis from the inhibition of clamp loading ( Figure S4C ). However, two experiments yielded similar inhibition profiles, suggesting that ongoing synthesis by α from a pre-loaded SC is at least as sensitive to inhibition as clamp loading. The reversible nature of clamp-loading (Leu, et al, 2000) , also provides a plausible explanation for the similar profiles: addition of an inhibitor followed by equilibration of the clamp-loading and unloading process erases the effects of pre-incubation.
NSAIDs were titrated into the total reaction system at concentrations up to 1 mM ( Figure 3C -E). Vedaprofen and bromfenac completely inhibited replication at 500 µM, while showing no effects below 63 µM. Carprofen showed weaker effects consistent with its weaker affinity for the SC (Table 1) , producing complete inhibition at SC binders flufenamic and tolfenamic acids and the non-SC binding NSAID ibuprofen showed much weaker effects or no inhibition of DNA replication ( Figure S4D-E) .
DISCUSSION
There is a pressing need for new classes of antibiotics (Bassetti et al., 2013) . The bacterial SC is an emerging target for the development of new antibacterial agents (Georgescu et al., 2008; Wijffels et al., 2011) . Its structure is highly conserved: studies indicate that clamps from several bacterial species have similar overall structures and CBM-binding sites (Burnouf et al., 2004; Argiriadi et al., 2006; Gui et al., 2011) . This study demonstrates that some NSAIDs are able to block subsite I, preventing SC binding to Pol III δ and/or α subunits and causing inhibition of DNA replication in vitro. Bacterial DNA replication in vivo is highly complex and involves many interacting components (Kelman and O'Donnell, 1995; Pomerantz and O'Donnell, 2007) .
By simplifying replication to a requirement for just four essential components, the SC, the clamp loader complex and the Pol III α subunit and SSB , we were able to directly link inhibition of SCmediated interactions by NSAIDs to inhibition of DNA replication in vitro, thus providing an explanation for the apparent correlation between E. coli SC inhibition and antibacterial effects. Since the CBM-binding pocket is well conserved across bacteria, E. coli SC inhibitors like vedaprofen, bromfenac and carprofen would also be expected to bind SCs from other species. All three were shown to be relatively weak inhibitors of the E. coli SC, consistent with their modest antibacterial activity compared to standard antibiotics. It is noteworthy that bromfenac demonstrated much weaker antibacterial activity against Gram-positive species than vedaprofen and carprofen. Furthermore, flufenamic and tolfenamic acids exhibited similar antibacterial effects to carprofen despite apparent weak SC affinity. These observations could be explained in part by differing membrane permeability and differences in the SC affinities of those compounds in the different species. While vedaprofen and carprofen have been used as adjuvants to antibiotics for their anti-inflammatory effects in the treatment of veterinary bacterial infections (Elitok and Elitok, 2004; Lopez et al., 2007; Kromker, et al., 2011) , the current work suggests that their co-administration may actually contribute independent (or perhaps synergistic) antibacterial effects.
The X-ray structures here, showing that the three NSAIDs bind in subsite I, should provide valuable insights into the design of more potent small-molecule SC inhibitors, potentially leading to the discovery of new classes of antibiotics with a novel mechanism of action. The conserved nature of the SC across bacterial species suggests potent SC inhibitors might show broad-spectrum activity. All three NSAIDs were shown to bury a hydrophobic moiety into the deep pocket of subsite I whilst positioning an aromatic ring(s) in the adjacent and shallower region. The three NSAIDs all contained carboxylic acids, which can form salt-bridges or H-bonds with adjacent residues; however, these interactions appeared to be confined to the edge of subsite I and did not seem to be a prerequisite for binding. While all three NSAIDs fully occupied subsite I, their relatively weak binding suggests there is only limited potential for designing more potent SC inhibitors that target subsite I alone. Of the three NSAIDs, only carprofen adopted a binding pose that "opened" the M362 gate separating the two subsites, inducing a CBM-binding pocket structure similar to that observed upon binding of peptide CBMs. It was also noted that the carbazole nitrogen of carprofen is directed towards subsite II, suggesting it might be a useful synthetic handle for projecting extra functionality towards this subsite in searching for non-peptidic SC-binders with higher affinity. 
SIGNIFICANCE
EXPERIMENTAL PROCEDURES
Compounds and Peptides
NSAIDs (purity> 95%) were purchased from Vitas-M Laboratory, Labotest or Sigma-Aldrich. Peptides were custom synthesized by GL Biochem (China) and showed >95% purity, as confirmed by HPLC-MS.
Protein Expression and Purification
Expression and purification of the E. coli SC, Pol III α subunit, SSB and the clamp loader complex γ 3 δδ' were carried out as described previously (Wijffels et al., 2004; Mason et al., 2013; Jergic et al., 2013) .
Crystallization and X-Ray Data Collection
Crystals of the E. coli SC were grown at 285 K by the hanging-drop vapor diffusion method. The drop was composed of 1 µl of sliding clamp (53 mg/ml in 10 mM Tris-HCl pH 7.2, 1 mM dithiothreitol, 1 mM EDTA and 15% glycerol) mixed with an equal volume of reservoir solution consisting of 100 mM MES pH 6.5, 100-150 mM CaCl 2 and 25-30% (v/v) PEG400.The reservoir volume was 1 ml. SC crystals were transferred to a CaCl 2 -free reservoir solution and ligands were soaked into the crystal at 2-5 mM in reservoir solution with <10% DMSO. All crystals were mounted using MiTeGen™ loops on pins with magnetic caps. For in-house data collection, crystals were flash-frozen to 100 K using an Oxford Cryo-stream. Diffraction data were collected using a MAR345 desktop beamline using CuKα X-rays from a Rigaku 007HF rotating anode generator with Varimax™ optics. For synchrotron data collection, the SSRL Automated Mounting system (SAM) was used. Mounted crystals were flash-frozen in liquid nitrogen and placed in the SAM cassettes. Diffraction data were collected at 100 K at the Australian Synchrotron, Beamline MX1 using X-rays of wavelength 0.95 Å.
Data Processing, Structure Solution and Refinement
Crystal data sets were integrated, merged and scaled with either HKL2000 (Otwinowski and Minor, 1997) or MOSFLM and SCALA (Winn et al., 2011) The structures were solved by molecular replacement with CCP4 using the Protein Data Bank entry 1MMI (Oakley et al., 2003) or 4K3S (Yin et al., 2013) as the starting model.
Iterative cycles of model building and refinement were performed in COOT (Emsley and Cowtan, 2004 ) and REFMAC5 (Skubak et al., 2004) .
Bioinformatics
Sequence alignment of bacterial sliding clamps (NCBI IDs: YP_859300.1, WP_004930066.1, ZP_05582848.1, ZP_08441263.1, NP_064722.1, NP_373240.1, WP_003242509.1, YP_815419.1 and AAF98349.2) was carried out using COBALT (Papadopoulos and Agarwala, 2007) .
Fluorescence Polarization Assay
FP experiments followed the published protocol (Yin et al., 2013) . Brifely, All FP experiments were conducted using a POLARstar Omega plate reader with non-treated black sterile 96-well plates (Greiner, USA). The buffer contained 10 mM HEPES pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, 0.07% Nonidet P-40 and 5%
DMSO. The fluorescent tracer used was N-fluorescein (FAM)-QLDLF-OH (GL Biochem, China), which has a K d of 70 nM for SC monomers. For the competition assay, 10 nM peptide and 50 nM sliding clamp monomers were used. Blank control (buffer), negative control (buffer and the peptide) and positive control (buffer, peptide and the sliding clamp) were used for data standardization. Experiments were carried out in duplicate. Curves were fit using GraphPad Prism v5.01 (GraphPad Software, USA). Binding-saturation curve fitting was applied to tracer binding. Dose-response curve fitting was applied to competition assays with variable slope.
Antibacterial Activity
Determination of minimum inhibitory concentrations (MICs) were carried out with the four bacterial strains 
DNA Replication Assay
The RNA-primed DNA template was prepared in advance by mixing 35 nM wild-type M13 ssDNA with 1 µM oligoribonucleotide (5'-UAUGUACCCCGGUUGAUA-AUCAGAAAAGCCCCA;
GeneWorks, Australia) in 30 mM Tris-HCl pH 7.6, 15 mM MgCl 2 , 130 mM NaCl and 0.1 mM EDTA for 10 min at 55°C and cooling to room temperature over a period of 8 h. DNA replication assays contained: 20 mM TrisHCl pH 7.6, 10 mM MgCl 2 , 0.8 mM ATP, 8.4 mM dithiothreitol, 0.6 mM of each dNTP, 211 nM Pol III α subunit, 700 nM SSB (as tetramers), 210 nM Pol III β subunit (as dimers), 42 nM γ 3 δδ' clamp loader complex, 120 mM NaCl and 3 nM RNA primed DNA template, in a volume of 6.8 µl. Compounds/peptide were dissolved in DMSO and diluted in series 2-fold (in 50% v/v DMSO) before being added (0.5 µl) to the assay mixture at 0˚C. The final DMSO concentration was 3.4% (v/v) in all assays. The assay mixtures were treated at 30°C for 60 min before being quenched by the addition of EDTA to 150 mM and SDS to 1% (w/v). The DNA products were separated by 0.7% agarose gel electrophoresis in TAE buffer (80 mM Tris, 40 mM acetic acid, 4 mM EDTA) and then stained with 10,000-fold diluted SYBR Gold (Life Technologies) for 60 min. The DNA products were visualized using a UV transilluminator. 
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Loxoprofen > 5000 > 5000 > 5000 > 5000 > 5000
Ketoprofen > 5000 > 5000 > 5000 > 5000 5000 Naproxen > 5000 > 5000 > 5000 > 5000 > 5000
Tolmetin > 5000 > 5000 > 5000 > 5000 > 5000 DMSO* > 5000 > 5000 > 5000 > 5000 > 5000 AcQLDLF** 0.9 > 5000 > 5000 > 5000 > 5000 * DMSO was included as a negative control by testing a 2-fold dilution series starting from 5%, as carried out with NSAIDS. ** AcQLDLF was included as a SC-binding positive control 
